熱門資訊> 正文
CytoMed Therapeutics董事长将有效持股增加至21.95%
2025-10-22 20:46
- CytoMed Therapeutics (NASDAQ:GDTC) said on Wednesday that its executive chairman and substantial shareholder, Peter Choo, has increased his shareholding in the company through recent open-market purchases of 105,824 shares.
- This is on top of 187,500 shares, which he holds personally, bringing his personal stake in CytoMed to 2.50% as of today.
- In addition, he is also a 55% shareholder of Glorious Finance and the sole shareholder of EP Capital, representing 2.28M shares, or 19.45% of the company.
- In aggregate, he owns 2.39M shares, representing 21.95% of the company’s total outstanding shares.
- CytoMed Therapeutics (NASDAQ:GDTC) shares were up more than 7% in premarket trading.
More on CytoMed Therapeutics
- CytoMed Therapeutics Limited (GDTC) Q2 2025 Earnings Call Prepared Remarks Transcript
- Financial information for CytoMed Therapeutics
推薦文章
美股機會日報 | 凌晨3點！美聯儲將公佈1月貨幣政策會議紀要，納指期貨漲近0.5%；13F大曝光！巴菲特連續三季減持蘋果
美股機會日報 | 阿里發佈千問3.5！性能媲美Gemini 3；馬斯克稱Cybercab將於4月開始生產
港股周報 | 中國大模型「春節檔」打響！智譜周漲超138%；鉅虧超230億！美團周內重挫超10%
一周財經日曆 | 港美股迎「春節+總統日」雙假期！萬億零售巨頭沃爾瑪將發財報
從軟件到房地產，美國多板塊陷入AI恐慌拋售潮
Meta計劃為智能眼鏡添加人臉識別技術
危機四伏，市場卻似乎毫不在意
財報前瞻 | 英偉達Q4財報放榜在即！高盛、瑞銀預計將大超預期，兩大關鍵催化將帶來意外驚喜？
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
